中国泰凌医药集团
CHINA NT PHARMA GROUP

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1011)

APPOINTMENT OF AUDITOR

This announcement is made by the board (the "**Board**") of directors (the "**Director(s)**") of China NT Pharma Group Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

Reference is made to (i) the announcement of the Company dated 4 June 2026 in relation to, among other things, the poll results of the annual general meeting of the Company held on 4 June 2026 and the retirement of Moore CPA Limited ("**Moore**") as the auditor of the Company; (ii) the supplemental announcement of the Company dated 12 June 2026; (iii) the circular of the extraordinary general meeting ("**EGM**") of the Company dated 10 August 2026 (the "**Circular**"), the notice of the EGM dated 10 August 2026, announcement of Company dated 28 August 2026 in relation to the poll results of the EGM held on 28 August 2026, (collectively, the "**Announcements**"), in relation to, among other matters, the change of auditor of the Company. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

The Board hereby announces that, having considered the recommendation of the audit committee of the Company (the "**Audit Committee**"), it has resolved to appoint HLB Hodgson Impey Cheng Limited ("**HLB**") as the new auditor of the Company to fill the casual vacancy following the retirement of Moore with effect from the date of approval by the Shareholders at the EGM and to hold office until the conclusion of the next annual general meeting of the Company.

CHRONOLOGY OF KEY EVENTS LEADING TO THE APPOINTMENT OF AUDITOR

Date	**Event**
28 August 2026	On 28 August 2026, the EGM was held in relation to the appointment of CCTH CPA Limited ("**CCTH**") as the auditor of the Company. As less than 50% votes were cast in favour for the proposed resolution regarding the appointment of CCTH as the auditor of the Company, the proposed resolution was not passed as an ordinary resolution by the Shareholders. The Audit Committee instructed the Company to seek quotations from other professional accounting firms and the Board continues its efforts to identify a suitable auditor to fill the causal vacancy.
31 August 2026	The Company issued quotation invitations to potential audit firms, one of which is HLB, to provide audit fee proposal for the FY2026.
2 September 2026	The Board discussed with these audit firms to assess their capabilities and other relevant information.
4 September 2026	The Company received brief audit fee proposals from HLB and other professional accounting firms respectively. The Board shortlisted HLB as the potential auditor.
8–9 September 2026	The Audit Committee discussed with HLB to understand their independence, objectivity, technical competence, industry knowledge, and engagement performance in order to evaluate the audit firm's audit quality, proposed audit timetable, resources assigned and other relevant information. The Audit Committee made recommendation to the Board on the change of auditor.
10–11 September 2026	The Board, after due consideration and with the recommendation from the Audit Committee, resolved to appoint HLB as the auditor of the Company to fill casual vacancy.

ASSESSMENT OF HLB

When assessing the selection of HLB for recommendation to the Board as the new auditor of the Company, the Audit Committee has taken into account the criteria set out in the Guidelines for Effective Audit Committees – Selection, Appointment and Reappointment of Auditors published by the Accounting and Financial Reporting Council. In particular, the Audit Committee has considered the following factors:

(i) Governance and leadership

HLB has been established in Hong Kong for more than 70 years with network firms covering 155 countries and employing over 50,000 staff globally. The Audit Committee reviewed HLB's system of quality management, which is established in accordance with the guidance issued by the Hong Kong Institute of Certified Public Accountants. The Audit Committee further noted that HLB demonstrates a strong commitment to audit quality through robust policies, ongoing training, and a culture that prioritizes professional standards and it maintains a structured internal monitoring regime. Overall, the Audit Committee is satisfied that HLB's system of quality management provides reasonable assurance that high-quality audits are delivered consistently.

(ii) Compliance with relevant ethical requirements

The Audit Committee reviewed HLB's policies and procedures for ensuring that all engagement partners, engagement quality control reviewers, and audit team members understand and comply with the relevant ethical requirements. The Audit Committee noted that HLB achieves this through mandatory training, clear communication, and annual written confirmations of independence. Compliance with ethical requirements is monitored through ongoing activities, including periodic engagement reviews and independence safeguards. The Audit Committee further noted that HLB conducts a formal evaluation of its quality management system at least annually, with any deficiencies identified being subject to root cause analysis and remediation.

HLB has confirmed to the Audit Committee that recent compliance tests have not identified any material deficiencies. HLB has also confirmed its independence and compliance with the HKICPA Code of Ethics, and no non-audit services are proposed. Based on the above, the Audit Committee is satisfied that HLB has appropriate policies and procedures in place to ensure ongoing compliance with applicable ethical requirements.

(iii) Industry knowledge and technical competence

The Audit Committee has evaluated HLB's experience by reviewing its track record in auditing entities of similar size and industry sector. The Audit Committee noted that HLB has demonstrated relevant industry expertise through its portfolio of listed company audits, including engagements in the pharmaceutical and healthcare sectors, which are comparable to the Company's operations. In particular, HLB serves a broad and established client base in these sectors, including companies engaged in pharmaceutical manufacturing, biopharmaceutical research and development, medical services, and healthcare products distribution. The Audit Committee considers that this portfolio demonstrates HLB's deep understanding of the industry-specific risks, revenue recognition practices, and accounting standards applicable to the Company's operations. The Audit Committee is satisfied that HLB possesses the necessary sector-specific knowledge and experience, as well as sufficient competent staff, to perform a quality audit of the Company.

(iv) Resources and capability and engagement performance

The Audit Committee has evaluated whether HLB has assigned sufficient and appropriate resources to perform a quality audit. The Audit Committee considered whether the nature, timing and extent of direction, supervision and review of the engagement team's work are commensurate with the size and complexity of the Company, the risks of material misstatement, and the technical competence and experience of individual team members. The Audit Committee noted that the audit team is headed by an Engagement Director, who has over 20 years of experience auditing listed companies across different industries, will oversee the overall execution, allocation of audit resources and monitoring of project milestones. Its core leadership comprises four senior-level professionals – the Engagement Director, Engagement Quality Control Reviewer, Director, and Engagement Manager – who collectively possess between 10 and over 20 years of professional experience.

The Audit Committee further noted that the allocation of approximately 400 hours at the Director level reflects appropriate senior-level involvement in directing and supervising the audit, while the 380 hours allocated to the Engagement Manager and 1,000 hours to the Senior Accountant and Accountant levels demonstrate adequate resourcing for the execution of detailed audit procedures.

HLB has also proposed a viable timetable for completion of the audit of the Annual Results, including the allocation of time and resources to each audit phase. After due consideration, the Audit Committee was satisfied that HLB's core audit team has sufficient capabilities and resources, including expertise and time, to perform a quality audit, and that the proposed timetable is viable, subject to ongoing monitoring of progress against milestones.

(v) Communication and interaction

The Audit Committee has reviewed HLB's communication protocols, which include scheduled meetings (detailed in the "Proposed timetable of the audit" below), regular updates, and prompt responses to queries. The Audit Committee is satisfied that HLB's approach will facilitate transparency, effective oversight, and constructive dialogue throughout the audit process. The Audit Committee considers that this proactive engagement will ensure that key issues are addressed promptly, that audit progress is monitored closely, and that the Audit Committee is kept fully informed of audit developments.

(vi) Monitoring process

The Audit Committee has established a framework for ongoing monitoring of HLB's audit engagement, which includes: (a) regular updates from HLB on audit progress against milestones; (b) review of significant audit findings and judgments prior to the issuance of the audit report; and (c) assessment of HLB's adherence to professional standards and ethical requirements throughout the engagement. Based on enquiries made to HLB and review of available information, the Audit Committee is not aware of any behavior or activities from HLB that would threaten its integrity, objectivity and independence.

PROPOSED TIMETABLE OF THE AUDIT

HLB has developed a concise, materiality driven and risk-based audit plan tailored to the Group's operations and financial reporting risks. The approach begins with understanding the Group's business, internal controls and key risk areas, particularly the issues of the Subject Transactions, and focuses audit work on the subsidiaries and relevant transactions most likely to affect the financial statements.

The following proposed audit plan and timetable is provided by HLB:

Phase	Period	Key procedures and events
Planning	October 2026	– Prepare the overall audit plan – Obtain an understanding of the Company and its environment, the applicable financial reporting framework and the Company's system of internal control – Identify and assess the risks of material misstatement – Meet with the management of the Company to discuss key issues upfront
Focused approach	October 2026 to December 2026	– Perform audit on opening balances and comparative financial information – Perform hard close audit – Discuss and resolve key issues with the management of the Company before year end – Meet with the Audit Committee to communicate audit plan
Audit fieldwork	January 2027 to March 2027	– Commence audit fieldwork – Perform substantive audit procedures – Meet with the management of the Company to discuss and resolve issues, and report observations and recommendations
Reporting and evaluation	March 2027	– Meet with the management of the Company for evaluation and debriefing – Meet with the Audit Committee to communicate audit results – Complete the annual audit – Issue audit opinion

The Audit Committee has reviewed the timetable above and confirmed that the audit progress remains on the track as at the date of this announcement.

Based on the above, the Audit Committee has assessed and considered HLB is eligible and suitable to act as the auditor of the Company for the consolidated financial statements of the Group for the year ending 31 December 2026. The Board and the Audit Committee are of the view that the appointment of HLB as the auditor of the Company would maintain audit quality and enhance the effectiveness of the Company's annual audit and is in the interest of the Company and the shareholders as a whole.

The estimated audit fee for audit services as quoted by HLB for the audit of the consolidated financial statements of the Company and its subsidiaries for the financial year ending 31 December 2026 is expected to be approximately RMB896,000 (exclusive of out-of-pocket expenses). The estimated audit fee has been determined after due consideration and arm's length negotiations between the Company and HLB, taking into account, among other things, the size, nature and complexity of the Group's business operations, the expected scope of the audit, the audit timetable, and the level and mix of professional staff to be deployed.

The appointment of HLB as the auditor of the Company is subject to the approval of the shareholders of the Company by way of an ordinary resolution at an EGM. A circular containing, among other things, details of the proposed appointment of HLB as the auditor and a notice of the EGM will be despatched to the shareholders of the Company in due course. The Board would like to take this opportunity to welcome HLB as the auditor of the Company.

By Order of the Board of
China NT Pharma Group Company Limited
NG Tit
Chairman

Hong Kong, 14 September 2026

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng Anna Ching Mei; the non-executive Directors are Dr. Qian Wei, Ms. Chin Yu and Mr. Lou Yongbin; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Kwok Che Chung and Dr. Zhao Yubiao.